Leqvio Demonstrates Significant LDL-C Reduction in Patients at Risk of Atherosclerotic Cardiovascular Disease
Topline results from the Phase III V-MONO study of Leqvio found that twice-yearly Leqvio achieved clinically LDL-C lowering compared to both placebo and ezetimibe.
